Identification of micro-RNAs involved in post-myocardial infarction remodeling and heart failure
View Patent ↗The present invention relates to the identification of miRNAs that are involved in heart failure and the process of post-myocardial infarction remodeling in heart tissue. Modulation of these identified miRNAs as a treatment for myocardial infarction, cardiac remodelling, and heart failure is described.
1. A method of treating myocardial infarction in a subject in need thereof comprising administering to the heart or coronary vasculature of the subject an inhibitor of miR-146a or miR-146b, wherein the inhibitor is an antisense oligonucleotide or an antagomir, and wherein one or more symptoms of myocardial infraction is improved in the subject following administration of the inhibitor.
2. The method of claim 1 , wherein the antisense oligonucleotide or antagomir comprises a sequence that is at least partially complementary to a mature sequence of miR-146a or miR-146b.
3. The method of claim 1 , wherein the antisense oligonucleotide comprises at least one sugar and/or backbone modification.
4. The method of claim 1 , wherein the antisense oligonucleotide is about 8 to about 18 nucleotides in length.
5. The method of claim 1 , wherein the inhibitor is administered to the subject by intravenous administration or direction injection into cardiac tissue.
6. The method of claim 1 , further comprising administering to the subject a second cardiac therapy.
7. The method of claim 6 , wherein the second cardiac therapy is selected from the group consisting of a β blocker, an ionotrope, a diuretic, ACE-I, All antagonist, BNP, a Ca ++ -blocker, an endothelin receptor antagonist, or an HDAC inhibitor.
8. The method of claim 1 , wherein fibrosis in the infarct zone is reduced following administration of the inhibitor.
9. The method of claim 1 , wherein apoptosis of heart cells in the infarct zone is reduced following administration of the inhibitor.
10. The method of claim 1 , wherein the subject is a human.
11. The method of claim 2 , wherein the antisense oligonucleotide or antagomir comprises a sequence that it at least partially complementary to the sequence of SEQ ID NO: 18 or SEQ ID NO: 19.
12. The method of claim 11 , wherein the antisense oligonucleotide or antagomir comprises a sequence that it fully partially complementary to the sequence of SEQ ID NO: 18 or SEQ ID NO: 19.
13. The method of claim 3 , wherein the sugar modification is a bicyclic sugar nucleoside modification, a 2′-O-alkyl modification, or a 2′-fluoro modification.
14. The method of claim 13 , wherein the bicyclic sugar nucleoside modification is a locked nucleic acid.
15. The method of claim 2 , wherein the backbone modification is a phosphorothioate linkage.
16. The method of claim 1 , wherein the antisense oligonucleotide is about 12 to about 16 nucleotides in length.
17. The method of claim 10 , wherein the human is suffering from idiopathic dilated cardiomyopathy.